Llwytho...
Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy
Direct-acting antiviral (DAA) therapy has changed the landscape of hepatitis C virus (HCV) management and has changed the focus to the possibility of HCV elimination in the near future. Glecaprevir, an NS3/4A protease inhibitor, and pibrentasvir, an HCV NS5A inhibitor, have addressed many of the exi...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Drug Des Devel Ther |
|---|---|
| Prif Awduron: | , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Dove
2019
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6681154/ https://ncbi.nlm.nih.gov/pubmed/31534310 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S172512 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|